ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $3.30 Consensus Target Price from Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $3.30.

Separately, Wall Street Zen cut shares of ALX Oncology from a “hold” rating to a “sell” rating in a report on Friday, June 6th.

Insiders Place Their Bets

In other ALX Oncology news, CEO Jason Lettmann bought 71,163 shares of ALX Oncology stock in a transaction that occurred on Wednesday, September 17th. The stock was purchased at an average cost of $1.08 per share, for a total transaction of $76,856.04. Following the completion of the acquisition, the chief executive officer owned 305,121 shares of the company’s stock, valued at approximately $329,530.68. This represents a 30.42% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 21.00% of the company’s stock.

Institutional Trading of ALX Oncology

A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its stake in ALX Oncology by 7.3% in the 4th quarter. Northern Trust Corp now owns 343,066 shares of the company’s stock worth $573,000 after purchasing an additional 23,324 shares during the period. Two Sigma Investments LP boosted its stake in ALX Oncology by 6.7% in the 4th quarter. Two Sigma Investments LP now owns 704,131 shares of the company’s stock worth $1,176,000 after purchasing an additional 44,072 shares during the period. Nuveen Asset Management LLC boosted its stake in ALX Oncology by 55.6% in the 4th quarter. Nuveen Asset Management LLC now owns 164,790 shares of the company’s stock worth $275,000 after purchasing an additional 58,896 shares during the period. Invesco Ltd. acquired a new position in ALX Oncology in the 1st quarter worth approximately $46,000. Finally, AQR Capital Management LLC boosted its stake in ALX Oncology by 183.6% in the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after purchasing an additional 77,065 shares during the period. 97.97% of the stock is currently owned by institutional investors.

ALX Oncology Trading Up 4.6%

ALX Oncology stock opened at $1.83 on Wednesday. The firm has a 50 day simple moving average of $0.99 and a 200-day simple moving average of $0.69. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.52 and a quick ratio of 4.52. The stock has a market capitalization of $98.00 million, a PE ratio of -0.83 and a beta of 1.11. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.05.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). As a group, equities research analysts expect that ALX Oncology will post -2.76 EPS for the current fiscal year.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.